NCT06601127RecruitingPhase 2
Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).
A Phase 2, Randomised, Double-blind, Positive-controlled, Multicentre Study of Tiprogrel in the Treatment of Patients with Acute Minor Ischaemic Stroke or High-risk Transient Ischaemic Attack.
Source: ClinicalTrials.gov · Last updated 7 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is designed to evaluate efficacy and safety of tiprogrel in the treatment of patients with acute ischemic cerebrovascular events.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- First submitted
- 2 Sept 2024
- Start date
- 21 Feb 2025
- Primary completion date
- 1 Apr 2026
- Lead sponsor
- Tianjin Institute of Pharmaceutical Research Co., Ltd
- Diseases
- Stroke
- NCT number
- NCT06601127
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 600
- From 21 Feb 2025 to the primary completion date, 1 Apr 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Age ≥ 40 years
- Acute Minor Ischaemic Stroke：AIS is defined as acute onset of neurological deficit attributed to focal brain ischaemia, NIHSS ≤5, and either of the following imaging characteristics:
- Acute single infarction with ≥50% stenosis of a major intracranial or extracranial artery.
- Acute multiple infarctions attributed to large-artery atherosclerosis, including non-stenotic vulnerable plaques.
- TIA with high risk of stroke: ABCD2 score ≥ 6 at the time of randomization, and the following imaging characteristic:
- a）TIA with ≥50% stenosis of a major intracranial or extracranial artery. 3）Can be treated with study drug within 24 hours of symptoms onset\*(\*Symptom onset is defined by the "last seen normal" principle) 4）A man or woman of childbearing potential does not have any plan to have a child from signing the informed consent to 3 months after the last dose 5）Written informed consent Exclusion Criteria
- Bleeding or other pathological brain disorders including malformation, tumor, abscess or other major non-ischemic brain disease on baseline head CT or MRI
- Isolated or pure sensory symptoms, isolated visual changes, or isolated dizziness/vertigo without evidence of acute infarction on baseline head CT or MRI.
- Preceding mRS\> 2
- Contraindication to anti-platelet therapy
- Clear indication for anticoagulation
- Two or more antiplatelet drugs have been used continuously for ≥3 days before enrollment.
- Used heparin or oral anticoagulant drugs within 10 days before enrollment
- Undergone intravenous or arterial thrombolysis and mechanical thrombectomy within 24 hours before enrollment
- History of intracranial hemorrhage or amyloid angiopathy
- History of aneurysm
- Diagnosis or suspicious diagnosis of acute coronary syndrome
- History of asthma
- High-risk for bradyarrhythmia
- Anticipated requirement for long-term (\>5 days) non-steroidal anti-inflammatory drugs or NSAIDs within the 8th day of randomization
- History of gastrointestinal bleeding within 3 months before enrollment or major surgery within 30 days
- Iatrogenic causes of minor stroke or TIA
- Planned or likely revascularization within the next 3 months, scheduled for surgery or interventional treatment requiring study drug cessation
- Severe non-cardiovascular comorbidity with life expectancy \< 3 months
- Women of childbearing age who have not taken effective contraceptive measures and have a positive pregnancy test record, as well as women who are pregnant or breastfeeding
- Currently receiving an experimental drug or device
- Participation in another clinical study with an experimental product during the last 30 days
- Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders
- Hemoglobin \<90g/L %
- Permanent hypertension
- Subjects who were judged by the investigator to be unsuitable for this clinical study
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Tiantan Hosptial, Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Not yet recruiting |
| Central Hospital Affiliated to Shenyang Medical College Coordinator of this site? Confirm its status | Shenyang | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.